ReviewTargeted oncology2020

Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.

Diana Lüftner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.